TGTX241108C34000
- 0.45
- 0.000.00%
TG Therapeutics Newsroom
TG Therapeutics Call Volume Above Normal and Directionally Bullish
Express News | Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $22
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $38 to $55
TG Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
TG Therapeutics Boosts Revenue Outlook Amidst Growth
B. Riley Remains a Buyer of TG Therapeutics on Weakness Following Q3 Results
TG Therapeutics Price Target Raised to $55 From $49 at H.C. Wainwright
TG Therapeutics: Promising Growth Trajectory and Blockbuster Potential Justify Buy Rating
TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript Summary
TG Therapeutics Signs Manufacturing Supply Agreement With FUJIFILM Diosynth Biotechnologies
Express News | Fujifilm Diosynth Biotechnologies: TG Therapeutics Has Committed to a Multi-Year Manufacturing Supply Agreement for Briumvi® (Ublitiximab-Xiiy), Its U.S. FDA-Approved Therapeutic for Relapsing Forms of Multiple Sclerosis (Rms)
Why Yum China Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Napco Security Technologies Posts Downbeat Results, Joins Centrus Energy, Constellation Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
TG Therapeutics (TGTX) Lags Q3 Earnings Estimates
10 Health Care Stocks Moving In Monday's Pre-Market Session
Express News | TG Therapeutics Says It Is On Path For Continued Growth Into End Of The Year And Into 2025 And Further Toward Long-term
TG Therapeutics Gives Mixed Q3 Results, Gives FY Outlook
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q3 Revenue $83.9M
TG Therapeutics Q3 2024 GAAP EPS $0.02, Inline, Sales $83.88M Beat $81.71M Estimate
Express News | TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises Briumvi® (Ublituximab-Xiiy) Full Year Revenue Guidance